Summary
Optimal treatment for glioblastoma patients who progress after standard Treatment chemoradiotherapy remains unknown. We analyzed data from Trial RTOG 0525 to investigate the effect of reirradiation or systemic treatment on survival after progression. Salvage treatment options were found to be highly variable. Patients who received no salvage treatment had significantly shorter survival than those treated after progression. There was no significant survival difference among patients receiving systemic therapy (alone or with radiation) or radiation alone.
Purpose: To determine the impact on overall survival with different salvage therapies, including no treatment, reirradiation, systemic therapy, or radiation and systemic therapy, in participants of a phase 3 clinical trial evaluating dose-dense versus standard-dose temozolomide for patients with newly diagnosed glioblastoma. Methods and Materials: This analysis of patients from Trial RTOG 0525 investigated the effect of reirradiation or systemic treatment after tumor progression. Survival from first progression was compared between patients receiving no therapy, systemic therapy alone, radiation alone, and both modalities. The Cox proportional hazards model was used to compare the mortality hazard, controlling for potential confounders. Results: The analysis included 637 patients who progressed and had information on their management, excluding those who died less than half a month after progression. A total of 267 patients (42%) received neither reirradiation nor systemic treatment at progression, 24 (4%) received radiation alone, 282 (44%) received systemic treatment only, and 64 (10%) received both radiation and systemic therapy. Patients who received no treatment had a median survival of 4.8 months, lower than with radiation treatment alone (8.2 months), systemic therapy alone (10.6 months), and both radiation and systemic therapy (12.2 months). In survival models controlling for potential confounders, those who received radiation alone had modestly better survival (hazard ratio HR 0.74, 95% confidence interval [CI] 0.43-1.28), whereas those who underwent systemic therapy either without (HR 0.42, 95% CI 0.34-0.53) or with radiation therapy (HR 0.44, 95% CI 0.30-0.63) had better survival. There was no significant survival difference between patients who received radiation only and those who received systemic therapy (either with radiation or alone). Conclusions: Patients who received no salvage treatment had poorer survival than those who received radiation, chemotherapy, or the combination. However, patient selection for no treatment likely reflects poorer expected prognosis. There was no significant survival difference among those receiving radiation therapy, systemic therapy, or both. Ongoing clinical trials will help define the role of reirradiation after glioblastoma progression. Ó 2017 Elsevier Inc. All rights reserved.
Introduction
Optimal management for recurrent glioblastoma (GBM) has not been established. A plethora of monotherapy and combination therapies have been evaluated. Such approaches include surgery, reirradiation, systematic therapy either with chemotherapy and/or targeted therapeutics or antiangiogenic agents, tumor treatment fields, or some combination of these, as well as supportive care (1-6). A variety of chemotherapies have been evaluated for recurrent GBM, with modest results. Recently bevacizumab, an antivascular endothelial growth factor monoclonal antibody, was evaluated for recurrent GBM. Phase 2 studies demonstrated favorable 6-month progressionfree survival and objective responses with bevacizumab for recurrent GBM, which led to its approval by the US Food and Drug Administration in 2009 for use in recurrent GBM (7-10). Currently bevacizumab is one of the most commonly used treatment options for patients with recurrent GBM in the United States. On the other hand, for patients with limited volume recurrence, reirradiation seems to provide similar overall survival (OS) in comparison with those treated with bevacizumab (11-13). Despite some evidence of improvement in progression-free survival, no significant increase in OS has been demonstrated with any particular approach (1, 14).
Further investigations are needed to define the optimal choice of salvage therapy, and in particular the role of reirradiation and systemic treatment in patients with recurrent GBM.
Trial RTOG 0525 was a phase 3 clinical trial evaluating dose-dense versus standard-dose temozolomide for patients with newly diagnosed GBM (15) . Patients were enrolled between January 2006 and June 2008, and primary study findings were published in 2013, where more details of the study design and results can be found (15). All patients received 60 Gy partial-brain irradiation in 2-Gy daily fractions. After progression, patients participating in this trial received variable salvage therapies (reported as nonprotocol therapy). The information on the type of nonprotocol therapy is available for analysis. The purpose of this study was to determine the impact on OS with different salvage therapies, including no treatment, reirradiation, systemic therapy, or radiation and systemic therapy, in those Trial RTOG 0525 participants. Information from this analysis may help generate new hypotheses for future clinical trials.
Methods and Materials
A total of 833 patients were enrolled and randomized in Trial RTOG 0525. We analyzed postprogression prognosis
